-
摘要: 乳腺癌作为全球女性发病率最高的癌症,虽然辅助化疗、放疗、靶向治疗、内分泌治疗的使用已显著降低了患者的死亡风险,但仍有部分患者尤其是晚期患者无法从现有的治疗手段中获益。随着免疫治疗的不断发展,近年来中国的乳腺癌免疫治疗转化研究从基础到临床,从分子靶点、药物研发到临床试验,均取得了突破性的进展。本文将就中国乳腺癌免疫治疗转化研究中的治疗靶点、预测标志物、治疗手段等进行综述。Abstract: Among women, breast cancer is the most commonly diagnosed cancer worldwide. Although adjuvant chemotherapy, radiotherapy, targeted therapy, and endocrine therapy have significantly reduced the mortality risk, some patients can not benefit from existing treatments, especially those with advanced breast cancer. With the rapid progression of immunotherapy, substantial advances have been made in breast cancer translational studies. From basic research to clinical practice, China has recently achieved outstanding accomplishments in the field of breast cancer-targeting immunotherapy with respect to molecular target discovery, drug invention, and clinical trial design. This review will introduce the recent achievements of the breast cancer translational research in China regarding therapeutic targets, predictive markers, and immunotherapy therapeutic methods.
-
Key words:
- breast cancer /
- translational research /
- immunotherapy
-
[1] Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer: a review[J]. JAMA Oncol, 2019, 5(8):1205-1214. doi: 10.1001/jamaoncol.2018.7147 [2] Schimid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8 [3] Li Q, Wang YF, Jia WJ, et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade[J]. Clin Cancer Res, 2020, 26(7):1712-1724. doi: 10.1158/1078-0432.CCR-19-2179 [4] Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer[J]. N Engl J Med, 2022, 386(12):1143-1154. doi: 10.1056/NEJMoa2115022 [5] Qin G, Wang X, Ye SB, et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer[J]. Nat Commun, 2020, 11(1):1669. doi: 10.1038/s41467-020-15364-z [6] Fang WL, Zhou T, Shi H, et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion[J]. J Exp Clin Cancer Res, 2021, 40(1):4. doi: 10.1186/s13046-020-01786-6 [7] Wan WJ, Ao X, Chen Q, et al. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer[J]. Mol Cancer, 2022, 21(1):60. doi: 10.1186/s12943-021-01447-y [8] Zhang RN, Yang YJ, Dong WJ, et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1[J]. Proc Natl Acad Sci U S A, 2022, 119(8):e2114851119. doi: 10.1073/pnas.2114851119 [9] Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy[J]. Ann Oncol, 2016, 27(8):1482-1492. doi: 10.1093/annonc/mdw168 [10] Huang D, Chen XM, Zeng X, et al. Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer[J]. Nat Immunol, 2021, 22(7):865-879. doi: 10.1038/s41590-021-00939-9 [11] Zhou WB, Yu MX, Pan H, et al. Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer[J]. J Immunother Cancer, 2021, 9(4):e002343. doi: 10.1136/jitc-2021-002343 [12] Zhang YY, Chen HY, Mo HN, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer[J]. Cancer Cell, 2021, 39(12):1578-1593.e8. doi: 10.1016/j.ccell.2021.09.010 [13] Bai F, Zhang P, Fu Y, etal. Targeting ANXA1 abrogates Treg-mediated immune sup pression in triple-negative breast cancer[J]. J Immunother Cancer, 2020, 8(1):169-178. [14] Wei JL, Wu SY, Yang YS, et al. GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer[J]. J Immunother Cancer, 2021, 9(7):e002383. doi: 10.1136/jitc-2021-002383 [15] Ni C, Fang QQ, Chen WZ, et al. Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells[J]. Signal Transduct Target Ther, 2020, 5(1):41. doi: 10.1038/s41392-020-0129-7 [16] Gu Y, Liu YF, Fu L, et al. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG[J]. Nat Med, 2019, 25(2):312-322. doi: 10.1038/s41591-018-0309-y [17] Lu YW, Zhao QY, Liao JY, et al. Complement signals determine opposite effects of B cells in chemotherapy-induced immunity[J]. Cell, 2020, 180(6):1081-1097. doi: 10.1016/j.cell.2020.02.015 [18] Liu J, Lao LY, Chen JN, et al. The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer[J]. Nat Cancer, 2021, 2(4):457-473. doi: 10.1038/s43018-021-00196-7 [19] Li H, Yang P, Wang J, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk[J]. J Hematol Oncol, 2022, 15(1):2-7. doi: 10.1186/s13045-021-01223-x [20] Liu CC, Qiang JK, Deng QD, et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression[J]. Cancer Res, 2021, 81(23):5919-5934. doi: 10.1158/0008-5472.CAN-21-1337 [21] Yu B, Luo F, Sun BW, et al. KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer[J]. Adv Sci (Weinh), 2022, 9(3):e2105793. doi: 10.1002/advs.202105793 [22] Zhao S, Ma D, Xiao Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance[J]. Oncologist, 2020, 25(10):e1481-e1491. doi: 10.1634/theoncologist.2019-0982 [23] Chen L, Jiang YZ, Wu SY, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-plus): an open-label, single-arm, phase II trial[J]. Clin Cancer Res, 2022, 28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313 [24] Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2):178-186. doi: 10.1038/s41422-020-0375-9 [25] Shi ZW, Shen JF, Qiu JJ, et al. CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors[J]. Theranostics, 2021, 11(15):7175-7187. doi: 10.7150/thno.59056 [26] Su SC, Zhao JH, Xing Y, et al. Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages[J]. Cell, 2018, 175(2):442-457. doi: 10.1016/j.cell.2018.09.007 [27] Huang LX, Rong Y, Tang X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer[J]. Mol Cancer, 2022, 21(1):45. doi: 10.1186/s12943-022-01515-x [28] Chen L, Qin H, Zhao RF, et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines[J]. Sci Transl Med, 2021, 13(601):eabc2816. doi: 10.1126/scitranslmed.abc2816 [29] Xia L, Zheng ZZ, Liu JY, et al. Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition[J]. Cancer Immunol Res, 2021, 9(6):707-722. doi: 10.1158/2326-6066.CIR-20-0405
点击查看大图
计量
- 文章访问数: 597
- HTML全文浏览量: 110
- PDF下载量: 276
- 被引次数: 0